Literature DB >> 35707732

Sample size calculations for noninferiority trials for time-to-event data using the concept of proportional time.

Milind A Phadnis1, Matthew S Mayo1.   

Abstract

Noninferiority trials intend to show that a new treatment is 'not worse' than a standard-of-care active control and can be used as an alternative when it is likely to cause fewer side effects compared to the active control. In the case of time-to-event endpoints, existing methods of sample size calculation are done either assuming proportional hazards between the two study arms, or assuming exponentially distributed lifetimes. In scenarios where these assumptions are not true, there are few reliable methods for calculating the sample sizes for a time-to-event noninferiority trial. Additionally, the choice of the non-inferiority margin is obtained either from a meta-analysis of prior studies, or strongly justifiable 'expert opinion', or from a 'well conducted' definitive large-sample study. Thus, when historical data do not support the traditional assumptions, it would not be appropriate to use these methods to design a noninferiority trial. For such scenarios, an alternate method of sample size calculation based on the assumption of Proportional Time is proposed. This method utilizes the generalized gamma ratio distribution to perform the sample size calculations. A practical example is discussed, followed by insights on choice of the non-inferiority margin, and the indirect testing of superiority of treatment compared to placebo.
© 2020 Informa UK Limited, trading as Taylor & Francis Group.

Entities:  

Keywords:  Generalized gamma; non-proportional hazards; noninferiority; proportional time; relative time; sample size

Year:  2020        PMID: 35707732      PMCID: PMC9042171          DOI: 10.1080/02664763.2020.1753026

Source DB:  PubMed          Journal:  J Appl Stat        ISSN: 0266-4763            Impact factor:   1.416


  22 in total

1.  Assessing non-inferiority of a new treatment in a three-arm clinical trial including a placebo.

Authors:  Iris Pigeot; Juliane Schäfer; Joachim Röhmel; Dieter Hauschke
Journal:  Stat Med       Date:  2003-03-30       Impact factor: 2.373

2.  Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics.

Authors:  Ralph B D'Agostino; Joseph M Massaro; Lisa M Sullivan
Journal:  Stat Med       Date:  2003-01-30       Impact factor: 2.373

3.  Evaluation of active control trials in AIDS.

Authors:  T R Fleming
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

4.  Non-parametric assessment of non-inferiority with censored data.

Authors:  G Freitag; S Lange; A Munk
Journal:  Stat Med       Date:  2006-04-15       Impact factor: 2.373

5.  Sample size estimation for non-inferiority trials of time-to-event data.

Authors:  Adam Crisp; Paula Curtis
Journal:  Pharm Stat       Date:  2008 Oct-Dec       Impact factor: 1.894

6.  How to establish equivalence when data are censored: a randomized trial of treatments for B non-Hodgkin lymphoma.

Authors:  C Com-Nougue; C Rodary; C Patte
Journal:  Stat Med       Date:  1993-07-30       Impact factor: 2.373

7.  "Proving the null hypothesis" in clinical trials.

Authors:  W C Blackwelder
Journal:  Control Clin Trials       Date:  1982-12

8.  Deviation from the Proportional Hazards Assumption in Randomized Phase 3 Clinical Trials in Oncology: Prevalence, Associated Factors, and Implications.

Authors:  Lorenzo Trippa; Brian M Alexander; Rifaquat Rahman; Geoffrey Fell; Steffen Ventz; Andrea Arfé; Alyssa M Vanderbeek
Journal:  Clin Cancer Res       Date:  2019-07-25       Impact factor: 12.531

9.  Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues.

Authors:  R Temple; S S Ellenberg
Journal:  Ann Intern Med       Date:  2000-09-19       Impact factor: 25.391

10.  The design of simulation studies in medical statistics.

Authors:  Andrea Burton; Douglas G Altman; Patrick Royston; Roger L Holder
Journal:  Stat Med       Date:  2006-12-30       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.